SCHEMBL5679329

SCHEMBL5679329

CCOC(=O)c1c(O)ccc(C(=NN)c2ccc(C3=NNC(=O)CC3C)cc2)c1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 10/20 0.51
▸ PDE3A Q14432 10/20 0.51
▸ GPR119 Q8TDV5 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ KDM4E B2RXH2 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ TNNC1 P63316 1/20 0.39
▸ PDE4A P27815 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ HRH3 Q9Y5N1 3/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5677114 0.87 PDE3B (0.46) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL5677129 0.87 PDE3B (0.46) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL5679319 0.76 PDE3B (0.56) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL5679326 0.76 PDE3B (0.56) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL5681194 0.75 SMN1; SMN2 (0.51) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL5681207 0.75 SMN1; SMN2 (0.51) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL5675191 0.74 PDE3B (0.64) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL5679287 0.70 PDE3B (0.55) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL5679278 0.70 PDE3B (0.55) PDE3BPDE3AGPR119SMN1; SMN2MAPT
SCHEMBL10552483 0.69 PDE3B (0.55) PDE3BPDE3AGPR119SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265871-B1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORP (FI) 2006-02-08 — — EP disclosed
US-6699868-B2 INCREASE THE CALCIUM SENSITIVITY OF CONTRACTILE PROTEINS OF THE CARDIAC MUSCLE ORION CORPORATION (FI) 2004-03-02 — — US disclosed
US-20030158200-A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure ORION CORPORATION (FI) 2003-08-21 — — US disclosed
EP-1265871-A1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORPORATION (FI) 2002-12-18 — — EP disclosed
WO-2001068611-A1 PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE ORION CORPORATION (FI) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158200-A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure FABP3, TNNI3, TNNT2 PDE3B 1154/4885PDE3A 667/4885GPR119 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback